Detalhe da pesquisa
1.
VCAM-1 and VAP-1 recruit myeloid cells that promote pulmonary metastasis in mice.
Blood
; 121(16): 3289-97, 2013 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-23407548
2.
Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice.
Blood
; 119(13): 3164-75, 2012 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-22327225
3.
Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.
Int J Cancer
; 129(8): 1979-89, 2011 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21154772
4.
Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses.
Clin Cancer Res
; 15(11): 3781-90, 2009 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19470729
5.
Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down.
Int J Oncol
; 30(2): 453-60, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17203228
6.
ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
Cancer Res
; 62(24): 7247-53, 2002 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12499266
7.
Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect.
Oncotarget
; 7(47): 76613-76627, 2016 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27780936
8.
Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy.
Adv Drug Deliv Rev
; 57(1): 135-52, 2005 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-15518926
9.
The development of combretastatin A4 phosphate as a vascular targeting agent.
Int J Radiat Oncol Biol Phys
; 54(5): 1491-6, 2002 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12459376
10.
Enhancement of vascular targeting by inhibitors of nitric oxide synthase.
Int J Radiat Oncol Biol Phys
; 54(5): 1532-6, 2002 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12459382
11.
Synergy between vascular targeting agents and antibody-directed therapy.
Int J Radiat Oncol Biol Phys
; 54(5): 1524-31, 2002 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12459381
12.
Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503.
Anticancer Res
; 22(3): 1453-8, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12168822
13.
Hypoxia imaging using PET and SPECT: the effects of anesthetic and carrier gas on [Cu]-ATSM, [Tc]-HL91 and [F]-FMISO tumor hypoxia accumulation.
PLoS One
; 6(11): e25911, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-22102855
14.
Selective induction of tumor ischemia: development of vascular targeting agents for cancer therapy.
Curr Opin Investig Drugs
; 3(9): 1381-4, 2002 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-12498016
15.
Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors.
Cancer Res
; 68(7): 2301-11, 2008 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18381437
16.
Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models.
Int J Cancer
; 102(1): 70-4, 2002 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12353236
17.
Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS.
NMR Biomed
; 15(2): 99-105, 2002 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-11870905
18.
The biology of the combretastatins as tumour vascular targeting agents.
Int J Exp Pathol
; 83(1): 21-38, 2002 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-12059907